Quick Answer
Propanc Biopharma, Inc. reported Diluted EPS of $14.85 per share (loss) for fiscal year 2025.
Propanc Biopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$14.85 | +99.0% |
| 2024 | -$1420.53 | -78818.3% |
| 2023 | -$1.80 | +96.3% |
| 2022 | -$49.23 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.30 | +99.1% | +23.1% |
| September 30, 2025 | -$0.39 | +98.9% | +96.9% |
| March 31, 2025 | -$12.50 | +97.7% | +61.2% |
| December 31, 2024 | -$32.23 | +97.9% | +10.4% |
| September 30, 2024 | -$35.97 | -89825.0% | +93.4% |
| March 31, 2024 | -$545.79 | -129850.0% | +65.0% |
| December 31, 2023 | -$1559.55 | -294154.7% | -3898775.0% |
| September 30, 2023 | -$0.04 | +98.1% | +90.5% |
- Propanc Biopharma, Inc. showed an increase of +99.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Propanc Biopharma, Inc.’s diluted eps has grown by 69.8% (from $49.23 per share (loss) to $14.85 per share (loss)).
- The most recent figure is from Propanc Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: